Karyopharm Therapeutics, Inc. (KPTI)
9.11
+0.42
(+4.83%)
USD |
NASDAQ |
Jun 10, 16:00
9.11
0.00 (0.00%)
Pre-Market: 08:18
Karyopharm Therapeutics Profit Margin (Quarterly) : -63.86% for March 31, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -63.86% |
| December 31, 2025 | -299.9% |
| September 30, 2025 | -75.21% |
| June 30, 2025 | -98.22% |
| March 31, 2025 | -78.17% |
| December 31, 2024 | -100.8% |
| September 30, 2024 | -82.70% |
| June 30, 2024 | 55.61% |
| March 31, 2024 | -112.8% |
| December 31, 2023 | -124.0% |
| September 30, 2023 | -95.83% |
| June 30, 2023 | -86.83% |
| March 31, 2023 | -88.19% |
| December 31, 2022 | -114.7% |
| September 30, 2022 | -100.5% |
| June 30, 2022 | -123.6% |
| March 31, 2022 | -86.84% |
| December 31, 2021 | 30.66% |
| September 30, 2021 | -137.5% |
| June 30, 2021 | -237.1% |
| March 31, 2021 | -246.8% |
| December 31, 2020 | -123.7% |
| September 30, 2020 | -250.8% |
| June 30, 2020 | -138.5% |
| March 31, 2020 | -291.8% |
| Date | Value |
|---|---|
| December 31, 2019 | -268.8% |
| September 30, 2019 | -314.6% |
| June 30, 2019 | -457.3% |
| March 31, 2019 | -42.68K% |
| December 31, 2018 | -28.26K% |
| September 30, 2018 | -20.12K% |
| June 30, 2018 | -169.2% |
| March 31, 2018 | -384.6% |
| December 31, 2017 | -2.54K% |
| September 30, 2017 | |
| June 30, 2017 | -979.6K% |
| March 31, 2017 | -44.00K% |
| December 31, 2016 | -57.31K% |
| September 30, 2016 | -52.97K% |
| June 30, 2016 | -51.12K% |
| March 31, 2016 | |
| December 31, 2015 | -116.2K% |
| September 30, 2015 | -40.50K% |
| June 30, 2015 | -21.80K% |
| March 31, 2015 | |
| December 31, 2014 | -162.0K% |
| September 30, 2014 | -93.92K% |
| June 30, 2014 | -78.24K% |
| March 31, 2014 | -8.01K% |
| December 31, 2013 | -57.84K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 28.94% |
| Catalyst Pharmaceuticals, Inc. | 42.66% |
| Incyte Corp. | 23.83% |
| Inovio Pharmaceuticals, Inc. | -- |
| Cellectar Biosciences, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -168.7% |
| Gross Profit Margin (Quarterly) | 96.13% |
| Operating Margin (Quarterly) | -76.31% |
| Return on Net Operating Assets | -497.3% |